论文部分内容阅读
目的观察不同的新辅助化疗方案对结肠癌肝转移的疗效。方法将选取的结肠癌肝转移患者随机分为研究组和对照组,研究组采用FOLFOX方案,对照组采用FOLFIRI方案。结果研究组总有效率、疾病控制率均高于对照组,差异有统计学意义(P<0.01)。研究组的血液系统不良反应较对照组严重且差异显著(Z=-2.764,P<0.01),消化系统不良反应较对照组轻且差异显著(Z=-2.372,P<0.05),2组神经毒性相比差异不显著(Z=-1.521,P>0.05)。研究组中位无进展生存期、中位总生存期与对照组相比均明显延长且差异显著(P<0.05)。结论 FOLFOX方案较FOLFIRI方案对结肠癌肝转移患者具有明显优势、较高的临床应用价值。
Objective To observe the effect of different neoadjuvant chemotherapy regimens on hepatic metastasis of colon cancer. Methods Selected patients with liver metastases of colon cancer were randomly divided into study group and control group, the study group FOLFOX program, the control group FOLFIRI program. Results The total effective rate and disease control rate in the study group were higher than those in the control group, with significant difference (P <0.01). Adverse reactions in the study group were more severe than those in the control group (Z = -2.764, P <0.01). Adverse reactions in the digestive system were lighter and more significant than those in the control group (Z = -2.372, P <0.05) There was no significant difference in toxicity (Z = -1.521, P> 0.05). The median progression-free survival and median overall survival in study group were significantly longer than those in control group (P <0.05). Conclusion FOLFOX regimen has obvious advantages over FOLFIRI regimen in patients with liver metastases of colon cancer and has high clinical value.